FDA label
What is Afrezza used for?
Afrezza contains insulin human. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Afrezza?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Afrezza, powder, metered
Indications and Usage, quoted from the label by Mannkind Corporation (BLA022472). Cross-references to other label sections are left out.
AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus.
Limitations of Use:
- AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA).
- The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking.
Source: DailyMed label, set id 29f4637b-e204-425b-b89c-7238008d8c10, version 17, effective May 30, 2026. NDC 47918-874, one of 3 listings for this product.
Questions
What is Afrezza used for?
The FDA label says: “AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus.”
What drug class is Afrezza?
FDA lists insulin human in the Insulin established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.